Privately held Edison Pharmaceuticals Inc. wooed a big pharma partner, inking an R&D and commercialization agreement with Dainippon Sumitomo Pharma Co. Ltd. (DSP) to develop lead program EPI-743 and follow-on molecule EPI-589 in Japan.
Third Rock Ventures raised its third fund of $516 million, continuing with its mission to launch and invest in companies developing disruptive technologies in the field of health care. "We look for areas of science and translational medicine that have become ripe for a breakthrough fundamental advance," Third Rock partner Alexis Borisy told BioWorld Today. more »
Emerging diseases are by their nature a disconcerting foe. As with any preventive measure, it's only possible to know for sure if a new infectious agent has gotten in under the radar when patients begin to present with unusual symptoms.
Scientists have discovered that normal brain activity induces DNA damage, and that such damage is induced more strongly, and repaired more slowly, in the brains of mice with Alzheimer's disease. The findings suggest new possibilities for fighting neuronal damage in Alzheimer's disease, and such DNA breaks may also be a newly discovered mechanism of memory storage under normal circumstances.
- Broad, But Not Too Broad, Block of FGF Receptors Foils Tumors »
- 'Parallel Vasculature' Plays a Role in Cholesterol Transport »
- Immune Modulation Could Speed Bone Fracture Healing »
- New Antimalarial Compound Raises Hopes of Eradication »
- Anticancer Drugs May Hold Key to Parasite Treatment »
- Nanoparticles to Speed Up the End of Inflammation »
- Industry Pays it Forward in Training Young Researchers »
- Simple, Cheap Method Could Improve Stem Cell Transplant »
- Newly Identified Enzyme Could Rival PARPs as a Drug Target »
- Evolution: Survival of the Fittest, and Some OthersMarch 14, 2013 | 1:51 PM | Posted by: Anette Breindl
- ‘Indirect’ Fat Clogging NIH’s ArteriesMarch 12, 2013 | 1:20 PM | Posted by: Mari Serebrov
- Statistical Tinkering in Device Regulation a Disservice to PatientsMarch 07, 2013 | 2:05 PM | Posted by: Marie Powers
- Omontys Recall Rings Alarm Over BiosimilarsFebruary 27, 2013 | 9:00 AM | Posted by: Mari Serebrov
- Patients Take the Lead in Clinical Whole Genome SequencingFebruary 12, 2013 | 4:17 PM | Posted by: Catherine Shaffer
Cast Your Vote
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST